Table 2.

Annualized eGFR slopes (ml/min per 1.73 m² per year) for tolvaptan-treated patients versus controls

CKD Stage	Tolvaptan-Treated Patients			Controls
	Baseline eGFR	eGFR Slope		Baseline eGFR	eGFR Slope
		Baseline, Last Follow-Up, n=97	1 Mo, Last Follow-Up, n=97		All, n=194	Best Matched Follow-Up, n=97a
1	102±10	−1.49±2.88	−0.72±3.77b,c	102±13	−2.68±1.95	−2.72±2.34
	[18]	[18]	[18]	[36]	[36]d	[18]
2	75±9	−1.77±2.05e,f	−1.77±2.10e,f	74±9	−3.62±2.42	−3.88±2.47
	[34]	[34]	[34]	[68]	[68]d	[34]
3	46±10	−2.68±1.96e,f	−2.53±1.86e,f	46±10	−3.78±1.88	−4.20±1.59
	[37]	[37]	[37]	[74]	[74]d	[37]
4	25±3	−3.25±0.91c	−3.02±1.06c	28±2	−3.63±1.37	−4.43±1.06
	[8]	[8]	[8]	[16]	[16]d	[8]
Total	64±25	−2.20±2.18g,h	−1.97±2.44g,h	64±25	−3.50±2.09	−3.84±2.09
	[97]	[97]	[97]	[194]	[194]d	[97]
Follow-up, yr	—	4.64±2.79g,h	4.55±2.80g,h	—	7.91±3.97	6.97±3.56

Values are expressed as mean±SD. Numbers in brackets represent the numbers of patients. —, not applicable.

^aThe control with a duration closest to the matched patient was chosen in the adjusted control group.

^bSignificantly different from controls (all) at a P value of <0.05.

^cSignificantly different from controls (matched) at a P value of <0.05.

^dCharacterization of the controls is on the basis of CKD of its matched patient.

^eSignificantly different from controls (all) at a P value of <0.02.

^fSignificantly different from controls (matched) at a P value of <0.02.

^gSignificantly different from controls (all) at a P value of <0.001.

^hSignificantly different from controls (matched) at a P value of <0.001.